GSK press releases Follow Exdensur (depemokimab) approved in China for the treatment of chronic rhinosinusitis with nasal polyps (CRSwNP) Exdensur is the first and only ultra-long-acting biologic in China for CRSwNP https://www.gsk.com/en-gb/media/press-releases/exdensur-depemokimab-approved-in-china/ gsk.com
